Celcuity is a clinical-stage biotechnology company developing targeted cancer therapies focused on the PI3K/AKT/mTOR (PAM) pathway. Its lead candidate, gedatolisib, is a pan-PI3K and mTORC1/2 inhibitor being advanced primarily in HR-positive, HER2-negative advanced breast cancer and other solid tumors. With little to no commercial product revenue to date, its profile is defined by late-stage clinical development rather than marketed drugs.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -45.3 | — |
| Q3 2025 | 0 | — | -43.8 | — |
| Q4 2025 | 0 | — | -51 | — |
| Q1 2026 | 0 | — | -52.8 | — |
| Q2 2026 | 0 | — | -78.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: NetScout Systems, Inc. (NTCT), McGrath RentCorp (MGRC), DiamondRock Hospitality Company (DRH), Hawkins, Inc. (HWKN), Brighthouse Financial, Inc. (BHF), Enliven Therapeutics, Inc. (ELVN)